The following IPOs are expected to price this week:
Advanced Drainage Systems (WMS), the world's largest provider of high density plastic pipe used in construction, plans to raise $261 million by offering 14.5 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Advanced Drainage Systems would command a market value of $1.3 billion. Advanced Drainage Systems, which was founded in 1966, booked $1.1 billion in sales over the last 12 months. The Hilliard, OH-based company plans to list on the NYSE under the symbol WMS. Barclays, Deutsche Bank, Citi and RBC Capital Markets are the joint bookrunners on the deal.
Atara Biotherapeutics (ATRA), an early-stage biotech targeting muscle loss in patients with end-stage renal disease, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Atara Biotherapeutics would command a market value of $305 million. Atara Biotherapeutics, which was founded in 2012, booked $0 million in sales over the last 12 months. The Brisbane, CA-based company plans to list on the NASDAQ under the symbol ATRA. Goldman Sachs and Citi are the joint bookrunners on the deal.
El Pollo Loco Holdings (LOCO), a Tex-Mex fast food chain with 401 locations primarily in California, plans to raise $100 million by offering 7.1 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, El Pollo Loco Holdings would command a market value of $531 million. El Pollo Loco Holdings, which was founded in 1980, booked $319 million in sales over the last 12 months. The Costa Mesa, CA-based company plans to list on the NASDAQ under the symbol LOCO. Jefferies & Co., Morgan Stanley and Baird are the joint bookrunners on the deal.
Immune Design (IMDZ), an early-stage biotech developing immunotherapy oncology treatments, plans to raise $60 million by offering 4.7 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Immune Design would command a market value of $221 million. Immune Design, which was founded in 2008, booked $1 million in sales over the last 12 months. The Seattle, WA-based company plans to list on the NASDAQ under the symbol IMDZ. Jefferies & Co. and Leerink Partners are the joint bookrunners on the deal.
Innocoll (INNL), which develops absorbable collagen drugs to treat pain, foot infections and adhesions, plans to raise $75 million by offering 5.4 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Innocoll would command a market value of $292 million. Innocoll, which was founded in 1997, booked $5 million in sales over the last 12 months. The Athlone, Ireland-based company plans to list on the NASDAQ under the symbol INNL. Piper Jaffray and Stifel are the joint bookrunners on the deal.
Intersect ENT (XENT), which sells absorbable nasal implants for post-surgical sinusitis relief, plans to raise $60 million by offering 5.0 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Intersect ENT would command a market value of $291 million. Intersect ENT, which was founded in 2003, booked $23 million in sales over the last 12 months. The Menlo Park, CA-based company plans to list on the NASDAQ under the symbol XENT. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal.
Mapi-Pharma (MAPI), which is developing extended-release formulations of existing drugs and generics, plans to raise $37 million by offering 2.7 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Mapi-Pharma would command a market value of $215 million. Mapi-Pharma, which was founded in 2008, booked $0 million in sales over the last 12 months. The Ness Ziona, Israel-based company plans to list on the NASDAQ under the symbol MAPI. Aegis Capital is the lead bookrunner on the deal.
Medical Transcription Billing (MTBC), which provides a SaaS platform for ambulatory care facilities, plans to raise $20 million by offering 4.1 million shares at a price range of $5.00 to $5.00. At the midpoint of the proposed range, Medical Transcription Billing would command a market value of $56 million. Medical Transcription Billing, which was founded in 2001, booked $11 million in sales over the last 12 months. The Somerset, NJ-based company plans to list on the NASDAQ under the symbol MTBC. Chardan Capital Markets, Aegis Capital Corp. and Summer Street Research Partners are the joint bookrunners on the deal. (Revised terms on 07/14/14. Previously planned to offer 3 million shares at a range of $9-$11.)
Microlin Bio (MCLB), a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, plans to raise $28 million by offering 5.5 million shares at a price range of $4.50 to $5.50. At the midpoint of the proposed range, Microlin Bio would command a market value of $51 million. Microlin Bio, which was founded in 2013, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Brean Capital and Summer Street Research Partners are the joint bookrunners on the deal. (Revised terms for the fourth time on 7/3/14 and added warrants. Originally planned to offer 3.6 million common shares at a range of $6-$8.)
Ocular Therapeutix (OCUL), which develops eye therapies using a sustained-release hydrogel platform, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Ocular Therapeutix would command a market value of $325 million. Ocular Therapeutix, which was founded in 2006, booked $0 million in sales over the last 12 months. The Bedford, MA-based company plans to list on the NASDAQ under the symbol OCUL. Morgan Stanley, Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal.
Orion Engineered Carbons (OEC), a global producer of the chemical additive carbon black used in industrial rubber, plans to raise $405 million by offering 18.0 million shares at a price range of $21.00 to $24.00. At the midpoint of the proposed range, Orion Engineered Carbons would command a market value of $1.3 billion. Orion Engineered Carbons, which was founded in 1932, booked $1.8 billion in sales over the last 12 months. The Luxembourg-based company plans to list on the NYSE under the symbol OEC. Morgan Stanley, Goldman Sachs, UBS Investment Bank and Barclays are the joint bookrunners on the deal.
Pfenex (PFNX), which is developing a biosimilar version of Roche's Lucentis treatment for wet AMD, plans to raise $65 million by offering 8.1 million shares at a price range of $8.00 to $8.00. At the midpoint of the proposed range, Pfenex would command a market value of $155 million. Pfenex was founded in 2009. The San Diego, CA-based company plans to list on the NYSE/Amex under the symbol PFNX. William Blair and JMP Securities are the joint bookrunners on the deal. (Revised terms on 07/17/14. Previously planned to offer 5mm shares at a range of $12-$14.)
Spark Energy (SPKE), a natural gas and electricity retailer primarily in Illinois and California, plans to raise $60 million by offering 3.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Spark Energy would command a market value of $275 million. Spark Energy, which was founded in 1999, booked $324 million in sales over the last 12 months. The Houston, TX-based company plans to list on the NASDAQ under the symbol SPKE. Baird and Stifel are the joint bookrunners on the deal.
Townsquare Media (TSQ), an Oaktree-backed operator of 312 radio stations in small and mid-sized markets, plans to raise $125 million by offering 8.3 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Townsquare Media would command a market value of $394 million. Townsquare Media, which was founded in 2010, booked $294 million in sales over the last 12 months. The Greenwich, CT-based company plans to list on the NYSE under the symbol TSQ. BofA Merrill Lynch, Jefferies & Co. and RBC Capital Markets are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 8 IPO pricings. Sage Therapeutics (SAGE), which is developing treatments for life-threatening epileptic seizures, was the week's winner, ending up 67% from its IPO price.
